RxDoctor Payments DataLook up a doctor →

Jackie Shipley

Family · Des Moines, IANPI 1477926434

Payments from drug & device makers

$8,586in general payments, 2019–2025

Across 531 payments — averaging $16.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$1K
  • Boehringer Ingelheim$608
  • Lilly USA, LLC$583
  • AstraZeneca$565
  • Astellas Pharma US Inc$447
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$8,46299%
  • Education$1241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,586 in reported general payments places this provider in the 95th percentile of 1,268 family providers in Iowa.

See all family providers in Iowa

Medicare billing

Part B allowed, 2024
$22,814
Medicare patients
69
Services billed
721

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$83,916
JanuviaSitagliptin Phosphate66$54,188
JardianceEmpagliflozin40$40,007
EliquisApixaban44$36,008
TrulicityDulaglutide29$34,673
LinzessLinaclotide45$27,248
Stiolto RespimatTiotropium Br/Olodaterol Hcl28$18,443
XareltoRivaroxaban17$16,124
MounjaroTirzepatide13$13,942
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr25$10,424
Bevespi AerosphereGlycopyrrolate/Formoterol Fum24$10,188
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$9,410
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$9,204
Janumet XrSitagliptin Phos/Metformin Hcl14$9,144
Spiriva HandihalerTiotropium Bromide13$7,798

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$118$83,91674 claims
MerckJanuvia, Janumet Xr$242$63,33280 claims
Boehringer IngelheimJardiance, Stiolto Respimat$608$58,45068 claims
Lilly USA, LLCTrulicity, Mounjaro$583$48,61542 claims
PfizerEliquis$1,476$36,00844 claims
AbbVieLinzess$1,911$27,24845 claims
AstraZenecaBevespi Aerosphere, Breztri Aerosphere, Symbicort$565$22,79552 claims
GSKAnoro Ellipta, Trelegy Ellipta$46$19,62837 claims
Johnson & JohnsonXarelto$14$16,12417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,268 family providers in Iowa.

Other family in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →